Got migraines? A new FDA approved nasal spray may offer immediate relief.

  • Share:
  • facebook
  • linkedin
  • twitter
Migraine headaches are more common in women than in women by 3 to 1 according to UCLA Health meaning 18-25% of all women suffer from migraines. While many chronic migraine sufferers have turned to chiropractors for long-term relief or resolution of the condition, it can take a while for an acute episode to resolve or markedly improve. Pfizer's newly approved drug sold as Zavzpret may offer relief of acute symptoms. Conveniently applied as a nasal spray, drug trials showed it performed better than a placebo in relieving pain and patients’ most bothersome symptoms, according to clinical trial results published in the journal Lancet Neurology. In trials of about 1300 study participants, the drug was able to help people return to normal function in about 2 hours or less. While the drug, as in other medications for migraine may cause drowsiness, unlike pill-form medications, those who have nausea will appreciate the nasal spray. For those looking for more than just temporary relief, chiropractors have managed to help many sufferers reduce the number of migraines they have and resolve many other musculoskeletal complaints naturally.   Need help now; book online here. Want to read more about Zavzpret, check out the NY Times article

F.D.A. Approves New Nasal Spray for Migraines

Pfizer’s treatment applies an approach that is different from some other products, which doctors say may make it safer for people at risk of heart attacks or stroke.

By Christina Jewett March 10, 2023 The Food and Drug Administration has approved a Pfizer nasal spray for treatment of migraines that uses a different therapy from other nasal products on the market for severe headache pain, the company said on Friday. The fast-acting treatment, which is called zavegepant and will be sold as Zavzpret, performed better than a placebo in relieving pain and patients’ most bothersome symptoms, according to clinical trial results published in the journal Lancet Neurology. Participants in the trial who took the medication were more likely to report returning to normal function 30 minutes to two hours after taking it. The gains, though, were not significant for every patient. A study tracked the experience of 1,269 patients — half on the drug and half on a placebo — focusing on how they reported feeling two hours after using either substance. About 24 percent on the medication reported freedom from pain, compared to about 15 percent who took a placebo, according to the study. Read more